Related Experiment Video

Updated: Aug 2, 2025

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

10.1K

Apelin/ELABELA-APJ system in cardiac hypertrophy: Regulatory mechanisms and therapeutic potential

Bo Pang1, Yin-Ru Jiang1, Jia-Yao Xu1

  • 1China Medical University-The Queen's University of Belfast Joint College, Queen's University Belfast, Belfast, Northern Ireland, BT9 7BL, United Kingdom.

European Journal of Pharmacology
|April 16, 2023
PubMed

Insights

The apelin/ELABELA-APJ system offers a new therapeutic target for pathological cardiac hypertrophy, a key risk factor for heart failure. Research explores its mechanisms and potential drug development for treatment.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Heart failure is a major global health issue.
  • Pathological cardiac hypertrophy significantly increases heart failure risk.
  • The apelin/ELABELA-APJ system is emerging as a novel therapeutic target.

Purpose of the Study:

  • To review the role of the apelin/ELABELA-APJ system in cardiac hypertrophy.
  • To elucidate the intricate mechanisms involved.
  • To compare novel agonists and antagonists for APJ.

Main Methods:

  • Literature review of studies on apelin, ELABELA, and APJ.
  • Analysis of molecular pathways regulating cardiac hypertrophy.
  • Comparison of therapeutic agents targeting the APJ receptor.

Main Results:

  • Apelin and ELABELA modulate cardiac hypertrophy through various pathways.
  • The apelin/ELABELA-APJ system presents new therapeutic avenues.
  • Novel peptides and small molecules targeting APJ have been developed.

Conclusions:

  • The apelin/ELABELA-APJ system is a promising target for treating cardiac hypertrophy.
  • Understanding its mechanisms can lead to effective clinical interventions.
  • Ongoing research focuses on developing specific APJ agonists and antagonists.

Keywords:
Apelin analogueApelin/ELABELA-APJ systemCardiac hypertrophyHeart failureUpdate

More Related Videos

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

24.5K
Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy07:02

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy

Published on: September 9, 2020

6.4K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
19
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
474
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
18
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.6K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
20